Key result
SGLT2 inhibitors and GLP-1 receptor agonists stand as preferred agents in stable CAD and T2D.
Why the study?
To summarize and analyze available literature to provide clinicians with the best treatment strategies for type 2 diabetes in stable coronary artery disease.
Do glucose-lowering agents with proven cardiovascular benefits improve outcomes in patients with type 2 diabetes and stable coronary artery disease?
Do glucose-lowering agents with proven cardiovascular benefits improve outcomes in patients with type 2 diabetes and stable coronary artery disease?
The review emphasizes prioritizing SGLT2 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes and stable coronary artery disease to reduce cardiovascular risk.
Answers are grounded in this paper and cite their sources.
May guide agent selection in T2D with stable CAD; leaves open optimal sequencing and head-to-head data.
The review summarizes and analyzes the available literature to provide information to clinicians about the best treatment strategies for type 2 diabetes in stable coronary artery disease. This data should help health care professionals make decisions in routine practice. 2023 European and Russian guidelines on type 2 diabetes suggest giving preference to glucose-lowering agents with proven benefits for the cardiovascular system, followed by drugs with proven safety for the cardiovascular system.
No takes yet. Share an insight, caveat, or question.
Гришаев et al. (2024) conducted a review in Type 2 diabetes and stable coronary artery disease. Glucose-lowering agents (SGLT2 inhibitors and GLP-1 receptor agonists) was evaluated. SGLT2 inhibitors and GLP-1 receptor agonists are recommended as preferred glucose-lowering agents for patients with type 2 diabetes and stable coronary artery disease due to their proven cardiovascular benefits.
Synapse has enriched 10 related papers. Consider them for comparative context: